Ali Ozes
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$1.5MFederal grants as PI5 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
5 awards · $1.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 15, 2023 | NSF | SBIR Phase I SBIR Phase I:Targeting the Root Cause of Ewing’s Sarcoma | $275K | ALTAY THERAPEUTICS, INC. |
| Sep 14, 2023 | NSF | SBIR Phase I SBIR Phase I: Targeting the Root Cause of Ewing’s Sarcoma | $275K | ALTAY THERAPEUTICS, INC. |
| Sep 15, 2022 | NIH | SBIR Phase I Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer . | $400K | ALTAY THERAPEUTICS, INC. |
| Sep 1, 2022 | NIH | SBIR Phase I Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD) | $300K | ALTAY THERAPEUTICS, INC. |
| Jun 1, 2022 | NIH | SBIR Phase I The development of a transcriptional inhibitor for lung fibrosis. | $299K | ALTAY THERAPEUTICS, INC. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#1,326
Awards as PI#417
Patents#273
Companies
- ALTAY THERAPEUTICS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.